Trial: 202103160

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Phase

II (Cancer Control)

Principal Investigator

Thaker, Premal

Disease Site

Ovary

Learn more about this study at: clinicaltrials.gov